Strata Oncology enrols first patient in trial of cancer therapies

Strata Oncology has enrolled the first patient in a prospective pan-tumour therapeutic clinical trial of several cancer therapies in new, biomarker-guided patient groups.

The Strata Precision Indications for Approved THerapies (Strata PATH) trial will evaluate the safety and efficacy of cancer therapies which are approved by the US Food and Drug Administration (FDA) in oncology.

All these therapies showed safety profiles in the advanced setting.

In the trial, each therapy will be administered according to the dosing regimen approved by the FDA.

The Strata PATH trial will deliver treatment selection for all therapeutic modalities by leveraging the company’s new quantitative RNA and multivariate algorithms.

Strata Oncology co-founder and CEO Dan Rhodes said: “The Strata PATH trial is a crucial step in our mission to accelerate the impact of precision medicine for patients with cancer, in both the early-stage and late-stage settings.

“There is no time to spare when it comes to getting patients their best possible therapies, so we have taken the initiative to sponsor this trial to prospectively test novel biomarker-guided treatment hypotheses that we believe may result in new, highly-responsive pan-tumor molecular indications for FDA-approved therapies.”

The first patient for the trial has been enrolled at the Kettering Health site.

For devising the hypotheses, which is being tested in the latest trial, Strata used its clinical molecular database developed through the previous Strata Trial.

This database comprises DNA mutation profiles as well as quantitative RNA expression data.

For the Strata PATH trial, patients with advanced cancer and early-stage cancer with evidence of micrometastatic disease following initial treatment, will be enrolled.

Free Whitepaper

Revolutionising chromatography and clarification in biopharma production

Biopharma companies are under constant pressure to improve productivity, maintain product purity, and cut costs. Yet this is far from straightforward. Process intensification is desired, but there are barriers to making processes more efficient. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield. Single-stage clarification technologies, such as 3M™ Harvest RC Chromatographic Clarifier, could play a vital role in this journey, by simplifying what would otherwise be a time-consuming and complex clarification train. This document delves into the history of chromatography and clarification, addresses problems, proposes solutions, and offers a glimpse into what the future may look like after a revolution in biopharma production processing. Download to learn more.

By 3M

The information you provide are used by 3M Company and its group companies, in accordance with 3M Global Privacy Policy as shown at 3M.com/privacy, for the purpose of (i) following up with you via email or telephone on any event sponsored / co-organized / participated by 3M, your questions, interests or requests; (ii) making materials available to you; and (iii) inviting you to future events; and (iv) based on your consent, sending you newsletters, advertisements, surveys and information about promotions and offers of 3M Company and its group companies via email. Please use the Intake form to object. EMEA residents: please read 3M privacy notice, opt in language & exact information on 3M data controller relevant to your location here

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.